[Clinico-pharmacologic studies with a M1 receptor antagonist (substance AWD 26-06) in a phase I clinical trial].
The tolerability of the compound AWD 26-06 (which is to classify as a M1-antagonist in consequence of the pharmacological investigations) was investigated in 11 healthy male persons with increasing dosage from 5 to 150 mg. Dryness of the mouth and scratch in the throat were observed by a dosage of 50 mg onwards, a diminuation of the flow of saliva and the accommodation were observed by a dosage of 100 and 150 mg, respectively. The frequency of the heart, but not the blood pressure, is increased by 150 mg of AWD 26-06. The influence on the secretion of the gastric juice was investigated in normal conditions and after stimulation by Pentagastrin with a dosage of AWD 26-06 of 25 mg in comparison with a placebo on 7 healthy male persons. The volume of gastric juice was diminished by 35% in all fractions, but the secretion of HCl, measured as basal acid output and peak acid output, was diminished in 5 of the 7 persons by 20%. A further investigation in order to check the therapeutic effect in patients with ulcus ventriculi and ulcus duodeni, respectively, is necessary and useful.
Terhaag
B
B
Institut für Klinische Pharmakologie, Medizinischen Akademie Carl Gustav Carus, Dresden.
Gramatté
T
T
Feller
K
K
D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D003984:Dibenzazepines / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000187:drug effects*; D006801:Humans; D008297:Male; D010418:Pentagastrin; D011976:Receptors, Muscarinic / Q000187:drug effects*; D012636:Secretory Rate / Q000187:drug effects
D000897:Anti-Ulcer Agents; D003984:Dibenzazepines; D011976:Receptors, Muscarinic; C060713:AWD 26-06; D010418:Pentagastrin
Klinisch-pharmakologische Untersuchungen mit einem M1-Rezeptor-antagonisten (Substanz AWD 26-06) in der Stufe I der klinischen Erprobung.